Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
Pier Francesco Ferrucci(MultiMedica), Chiara Martinoli(European Institute of Oncology), Sara Gandini(European Institute of Oncology), Michele Maio(University of Siena), Massimo Guidoboni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Sara Valpione(Cancer Research UK Manchester Institute), Gian Carlo Antonini Cappellini(Istituto Dermopatico dell'Immacolata), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Paola Savoia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Jacopo Pigozzo(Istituto Oncologico Veneto), Francesco Spagnolo(Martin University), Emilia Cocorocchio(European Institute of Oncology), Paola Queirolo, Maresa Altomonte(University of Siena), Ester Simeone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Diana Giannarelli(Agostino Gemelli University Polyclinic), Mario Mandalà(University of Perugia)
Cited by 398
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k